Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial.
暂无分享,去创建一个
M. Lebwohl | J. Silverberg | T. Bieber | E. Simpson | C. Feeney | P. Biswas | H. Valdez | M. Dibonaventura | R. Rojo | A. Blauvelt | C. Lynde | F. Valenzuela | P. Criado | S. Eisman | Jacek Zdybski | W. Gubelin | Tahira Khan | M. Cameron | J. Zdybski
[1] J. Silverberg,et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. , 2021, The New England journal of medicine.
[2] C. Flohr,et al. Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study , 2021 .
[3] C. Banfield,et al. Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib , 2020, CPT: pharmacometrics & systems pharmacology.
[4] C. Flohr,et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial , 2020, The Lancet.
[5] J. Silverberg,et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis , 2020, JAMA dermatology.
[6] M. Ardeleanu,et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis† , 2019, The British journal of dermatology.
[7] G. Yosipovitch,et al. Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? , 2016, Clinical Reviews in Allergy & Immunology.
[8] L. Iversen,et al. Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial , 2015, The British journal of dermatology.
[9] L. Chan,et al. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis , 2013, JAK-STAT.
[10] L. Coates,et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort , 2010, Arthritis care & research.
[11] J. O’Shea,et al. Janus kinases in immune cell signaling , 2009, Immunological reviews.
[12] H. Williams,et al. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.
[13] M. Graeber,et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.
[14] A Y Finlay,et al. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use , 1995, The British journal of dermatology.
[15] A. Finlay,et al. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.
[16] G. Rajka,et al. Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.
[17] J. Silverberg,et al. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[18] Julia Brasch,et al. Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .